Intermittent Fasting and Blood Sugar: Key Facts

Intermittent fasting and blood sugar are closely linked, with growing evidence suggesting that structured fasting patterns can lower fasting glucose and improve insulin sensitivity. Whether you are managing prediabetes, type 2 diabetes, or simply looking to support metabolic health, understanding how different fasting approaches affect glucose levels is essential. This article covers the evidence behind intermittent fasting, relevant NHS and NICE guidance, the fasting patterns most likely to benefit glucose control, safety considerations for people on medication, and practical advice on monitoring your blood sugar throughout a fasting plan.

How does intermittent fasting affect your blood sugar levels?

Intermittent fasting lowers fasting blood glucose and improves insulin sensitivity by reducing insulin secretion during fasting periods, though much of the benefit is mediated by accompanying weight loss and varies considerably between individuals.

Intermittent fasting can lower fasting blood glucose and improve insulin sensitivity. When food intake is restricted to defined windows, insulin secretion falls during the fasting period, allowing cells to become more responsive to insulin over time. It is worth noting that weight loss is a major mediator of these glycaemic improvements, and it can be difficult to separate the effects of fasting patterns from those of the calorie reduction that often accompanies them.

During a fasting period, the body progressively shifts from using glucose as its primary fuel towards using stored glycogen and, eventually, fatty acids. This metabolic shift may reduce postprandial glucose spikes and can lower average blood glucose over the course of a day. The effect appears to be more pronounced in people who begin with elevated fasting glucose or insulin resistance, including those with prediabetes or type 2 diabetes, though individual responses vary.

The magnitude of these changes differs considerably between individuals. Factors including baseline metabolic health, the specific fasting pattern followed, overall dietary quality during eating windows, physical activity levels, and concurrent medications all influence outcomes. Intermittent fasting is not a uniform intervention, and its effects on blood sugar should be understood in that context rather than as a guaranteed result. People taking glucose-lowering medications face particular considerations, which are covered in the safety section below.

What the evidence says: NHS and NICE guidance on fasting diets

NICE does not recommend a specific fasting protocol for blood glucose management, but acknowledges that intermittent fasting produces broadly comparable HbA1c reductions to conventional calorie restriction over three to twelve months.

NICE does not currently recommend any single dietary pattern, including intermittent fasting, as a first-line intervention for blood glucose management in type 2 diabetes, though it acknowledges that a range of dietary approaches can be effective when sustained.^[1][2] NHS guidance on weight management and type 2 diabetes prevention recognises that low-calorie and time-restricted eating approaches may support weight loss, which in turn improves glycaemic control. However, the evidence base for intermittent fasting specifically remains less extensive than that for continuous calorie restriction.

Several systematic reviews and randomised controlled trials have found that intermittent fasting produces broadly comparable reductions in HbA1c and fasting glucose to conventional calorie-restricted diets over periods of three to twelve months, though study quality and duration vary.^[19][23] A 2022 review published in the journal Nutrients found that time-restricted eating was associated with meaningful reductions in fasting blood glucose in adults with overweight or obesity.^[17][18]

NICE guidance on obesity (NG246, updated 2024) and on type 2 diabetes prevention emphasises that any dietary intervention should be personalised, sustainable, and delivered with appropriate clinical support.^[4] Neither guideline endorses a specific fasting protocol as superior. People considering intermittent fasting for blood sugar management are encouraged to discuss this with their GP or diabetes care team before starting, particularly if they are taking glucose-lowering medications.

Which fasting patterns have the most impact on glucose control?

Time-restricted eating within a six to ten hour window, particularly earlier in the day, has the strongest evidence for improving fasting glucose and insulin sensitivity among commonly studied fasting patterns.

Time-restricted eating (TRE), particularly eating within a six to ten hour window each day, appears to have the most consistent evidence for improving fasting blood glucose and insulin sensitivity among the commonly studied fasting patterns. Research suggests that aligning food intake with the earlier part of the day, when insulin sensitivity is naturally higher, may produce greater glycaemic benefits than late eating windows, though further large-scale trials are needed to confirm this.^[20][21]

The 5:2 approach, which involves eating normally for five days and restricting intake to approximately 500 to 600 kilocalories on two non-consecutive days, has been studied in people with type 2 diabetes and prediabetes. Evidence suggests it can reduce HbA1c and fasting glucose comparably to daily calorie restriction, though adherence varies. Alternate-day fasting, where very low calorie intake alternates with unrestricted days, shows similar metabolic effects but tends to have lower long-term adherence rates.

For people managing blood sugar, the choice of fasting pattern should take into account:

• Medication schedule: Some glucose-lowering drugs, including sulfonylureas and insulin, carry a risk of hypoglycaemia during fasting periods and may require dose adjustment.^[8][9] SGLT2 inhibitors (such as dapagliflozin, empagliflozin, and canagliflozin) carry a risk of diabetic ketoacidosis (DKA), including euglycaemic DKA where blood glucose may not be markedly elevated, during periods of very low calorie or carbohydrate intake. Anyone taking an SGLT2 inhibitor should discuss this risk with their GP or diabetes team before starting any fasting plan, and should know the symptoms of DKA: nausea, vomiting, abdominal pain, rapid breathing, and feeling unwell.

• Type 1 diabetes: People with type 1 diabetes should only undertake intermittent fasting under specialist supervision. Basal insulin must never be omitted, and ketone monitoring is essential when glucose is elevated or when feeling unwell during a fasting period.

• Lifestyle compatibility: A pattern that fits daily routines is more likely to be sustained.

• Comorbidities: Kidney disease, eating disorder history, or pregnancy may make certain patterns unsuitable.

A GP or registered dietitian can help identify the most appropriate approach based on individual circumstances.

Side effects and warning signs to watch for when fasting

Hypoglycaemia is the most serious risk, defined as blood glucose below 4.0 mmol/L; symptoms of DKA, including nausea, abdominal pain, and rapid breathing, require urgent medical attention.

Hypoglycaemia (low blood sugar) is the most clinically significant risk associated with intermittent fasting, particularly for people taking insulin, sulfonylureas, or other glucose-lowering medications. A blood glucose reading below 4.0 mmol/L is generally considered hypoglycaemia. Symptoms include shakiness, sweating, confusion, palpitations, and in severe cases, loss of consciousness. If you experience these symptoms and your glucose is below 4.0 mmol/L, follow your diabetes team's agreed treatment plan; a common approach is to take 15 to 20 g of fast-acting carbohydrate (such as glucose tablets or a small glass of fruit juice), wait 10 to 15 minutes, and recheck your glucose. Anyone on these medications must not begin a fasting regimen without first discussing medication adjustment with their GP or diabetes team.

Beyond hypoglycaemia, common side effects during the initial weeks of fasting include:

• Headaches and light-headedness, often related to reduced carbohydrate intake and mild dehydration.

• Fatigue and difficulty concentrating, which typically improve as the body adapts over two to four weeks.

• Irritability and hunger, particularly during the first week.

• Constipation, if fibre intake falls during restricted eating windows.

More serious warning signs that warrant prompt medical attention include persistent vomiting, chest pain, severe dizziness, fainting, or symptoms of DKA (nausea, abdominal pain, rapid or laboured breathing, feeling very unwell). These should prompt a call to NHS 111 or, if symptoms are severe or rapidly worsening, attendance at an accident and emergency department.

People with a history of eating disorders, those who are pregnant or breastfeeding, children and adolescents, and individuals with certain chronic conditions should not undertake intermittent fasting without specialist guidance. Suspected adverse effects from any prescribed medication taken alongside a fasting plan can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

How to monitor your blood sugar safely during a fasting plan

Monitoring frequency should be agreed with a GP or diabetes nurse before starting; people on insulin or sulfonylureas need checks before, during, and after fasting periods to detect hypoglycaemia early.

Regular blood glucose monitoring is essential for anyone with diabetes or prediabetes who undertakes intermittent fasting, and the frequency of testing should be agreed with a GP or diabetes nurse before starting. For people using insulin or sulfonylureas, more frequent monitoring, including checks before, during, and after fasting periods, is advisable to detect hypoglycaemia early. Those managing blood sugar through diet alone may require less frequent testing, but baseline and periodic checks remain valuable.

Continuous glucose monitors (CGMs) and flash glucose monitoring devices, such as the Libre system, can provide real-time data on glucose trends throughout fasting and eating windows. NICE recommends CGM for people with type 1 diabetes (NG17) and for certain groups with type 2 diabetes on insulin (NG28).^[10][11] For others, a structured self-monitoring plan using a fingerprick glucometer is appropriate.

Practical steps to monitor safely include:

• Recording readings in a logbook or app to identify patterns across fasting and eating periods.

• Knowing your target range: Blood glucose targets should be individualised by your diabetes team, as NICE emphasises personalised HbA1c and glucose goals rather than a single figure for all adults. Your team can advise on the range that is right for you; Diabetes UK also provides patient-facing guidance on blood sugar level targets.

• Recognising trends: Consistently low readings during fasting may indicate a need for medication review; consistently high readings after eating may suggest the eating window diet quality needs attention.

• Staying hydrated: Adequate fluid intake supports stable glucose and reduces the risk of dehydration-related symptoms.

• Drivers with diabetes: If you drive, be aware that the DVLA has specific guidance on blood glucose monitoring and hypoglycaemia management for licence holders with diabetes; discuss this with your diabetes team.^[12][13]

For those exploring structured weight management support alongside dietary changes, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support. Any monitoring plan should ultimately be reviewed by a qualified clinician who can interpret results in the context of an individual's full medical history.

Scientific References

1. Type 2 diabetes in adults: management (NG28).
2. Dietary advice and interventions | Type 2 diabetes in adults (NG28).
3. Treatment for type 2 diabetes.
4. Overweight and obesity management (NG246).
5. SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis.
6. Life-threatening dapagliflozin-associated euglycaemic diabetic ketoacidosis in a postoperative patient.
7. Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: A review of 72 cases over a 4.5-year period.
8. Hypoglycaemia | Treatment summaries — BNF.
9. Low blood sugar (hypoglycaemia).
10. Type 1 diabetes in adults: diagnosis and management (NG17).
11. Type 2 diabetes in adults: management (NG28) — full guideline PDF.
12. Diabetes mellitus: assessing fitness to drive.
13. Diabetes and driving.
14. The Yellow Card scheme: guidance for healthcare professionals, patients and the public.
15. Adverse reactions to drugs | Medicines guidance — BNF.
16. Effect of Time-Restricted Eating on Weight Loss in Adults.
17. Effects of Time-Restricted Feeding and Ramadan Fasting on Body Weight, Body Composition, Glucose Responses, and Insulin Resistance: A Systematic Review of Randomized Controlled Trials.
18. The Effects of Intermittent Fasting and Continuous Energy Restriction with Exercise on Cardiometabolic Biomarkers, Dietary Compliance, and Perceived Hunger and Mood.
19. Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomised clinical trials.
20. Later eating timing in relation to an individual internal clock is associated with lower insulin sensitivity.
21. Effects of Time-Restricted Eating on Insulin Sensitivity, Glycemic Control, and Metabolic Outcomes in Low- and Middle-Income Countries: A Systematic Review.
22. Time-restricted eating and metabolic health: implications for nutritional strategies and weight loss.
23. Efficacy of intermittent fasting on blood glucose and weight in type 2 diabetes and prediabetes: A comparison with ad libitum and continuous energy restriction diets.

Frequently Asked Questions